moxonidine has been researched along with Overweight in 4 studies
moxonidine: structure given in first source
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 9.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 5.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| " We compared the effect of two sympatholytic antihypertensive drug treatments, the centrally acting imidazoline receptor-1 agonist moxonidine and peripherally acting beta-blocking agent atenolol on sensitive inflammatory markers in overweight postmenopausal women with diastolic hypertension." | 5.13 | Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. ( Antikainen, RL; Ebeling, PE; Erkkola, RU; Kaaja, RJ; Katzman, P; Kibarskis, A; Manhem, K; Pöyhönen-Alho, MK; Tuomilehto, JO, 2008) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 5.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 1.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hausberg, M | 1 |
| Hillebrand, U | 1 |
| Kisters, K | 1 |
| Pöyhönen-Alho, MK | 1 |
| Manhem, K | 1 |
| Katzman, P | 1 |
| Kibarskis, A | 1 |
| Antikainen, RL | 1 |
| Erkkola, RU | 1 |
| Tuomilehto, JO | 1 |
| Ebeling, PE | 1 |
| Kaaja, RJ | 1 |
| Sharma, AM | 1 |
| Wagner, T | 1 |
| Marsalek, P | 1 |
| Chazova, I | 1 |
| Almazov, VA | 1 |
| Shlyakhto, E | 1 |
2 trials available for moxonidine and Overweight
| Article | Year |
|---|---|
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.
Topics: Adiponectin; Antihypertensive Agents; Atenolol; C-Reactive Protein; Double-Blind Method; Female; Fin | 2008 |
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G | 2006 |
2 other studies available for moxonidine and Overweight
| Article | Year |
|---|---|
Addressing the relationship between sympathetic activity and inflammation.
Topics: Antihypertensive Agents; Atenolol; C-Reactive Protein; Female; Humans; Hypertension; Imidazoles; Inf | 2008 |
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; | 2004 |